Unilife Corp

Unilife — Q1 2012 Earnings Presentation

17 slides from Unilife's earnings presentation, Nov 9, 2011

  1. Slide 1: First Quarter 2012 Earnings Conference Call

    First Quarter 2012 Earnings Conference Call

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our mana

  3. Slide 3: First Quarter 2012 Overview

    First Quarter 2012 Overview Alan Shortall Chief Executive Officer

  4. Slide 4: Delivering on Unilife's Strategy: 1Q FY2012 Milestones

    Delivering on Unilife's Strategy 1Q FY2012 milestones Commenced initial Unifill supply to pharmaceutical customers Introduction of expanded portfolio of highly differentiated, market-leading drug delivery systems: Auto-injectors Infusion and injection pumps Drug reconstitution delivery systems (incl

  5. Slide 5: Innovative, Differentiated Solutions for Unmet Needs

    Innovative, Differentiated Solutions for Unmet Needs Diversified Portfolio of Delivery Systems

  6. Slide 6: Unifill Syringe

    Unifill Syringe Commenced initial supply of the Unifill syringe to customers in July 2011 Continuing to increase production capacity at Unilife's York, PA facility Strong customer acceptance with many opportunities advancing in commercial pipeline

  7. Slide 7: Rita Auto-Injector

    Rita Auto-Injector Leverages design and safety features of Unifill syringe Ultra compact size relative to conventional auto-injectors True end-of-dose indicator (audible, tactile click, plus visual window) Automatic needle retraction - patient never sees needle Unilife Auto-Injectors

  8. Slide 8: EZMix Prefilled Reconstitution Syringe

    Only prefilled reconstitution syringe with integrated safety Dual drug chambers in single delivery system Leverages materials and proven technology of Unifill syringe Addresses unmet patient safety needs Easy to use, fewer steps than conventional reconstitution systems EZMix

  9. Slide 9: Infusion and Injection Pumps

    Infusion and Injection Pumps Subcutaneous infusion and injection pumps Delivers large volume doses in 3mL to 15mL size Single-use, disposable, wearable system worn by patient AutoInfusor(tm) Automatic drug infusion or injection into subcutaneous tissue at push of button Can be pre-set for delivery t

  10. Slide 10: Devices for Target Organ Delivery

    Devices for Target Organ Delivery Devices delivering drug to target organ Examples of target organs include brain, ear and eye Scheduled to enter into drug clinical trials with pharmaceutical partner in early 2012 Strong financial opportunity with U.S. and international prevalence rates for the targ

  11. Slide 11: Unitract 1mL Syringes

    Unitract 1mL Syringes Awarded two-year supply contract for Unitract 1mL syringes by Premier Purchasing Partners Largest GPO in U.S. Primary business focus remains Unifill syringe and other advanced drug delivery systems

  12. Slide 12: Financial Data Overview

    Financial Data Overview Rich Wieland Chief Financial Officer

  13. Slide 13: Financial Data - Fiscal 1st Quarter 2012

    Revenues for the quarter of $2.1M, compared to $3.5M for 1Q 2011 Product sales from discontinued contract manufacturing operations decreased by $1.6M Net loss for the quarter was $9.7M, or $0.16 per diluted share, compared to a net loss of $7.2M, or $0.14 per diluted share for 1Q 2011 R&D expenses i

  14. Slide 14: Financial Data - Fiscal 1st Quarter 2012 Continued

    Adjusted net loss of $6.5M, or $0.11 per diluted share, compared to an adjusted net loss of $3.9M, or $0.07 per diluted share for 1Q 2011 Excludes approx. $3.2M in non-cash share-based compensation expense, depreciation and amortization and interest expense compared to $3.4M in non-cash items in 1Q

  15. Slide 15: Looking Ahead in FY2012

    Looking Ahead in FY2012 Alan Shortall Chief Executive Officer

  16. Slide 16: Looking Forward

    Continued Unifill supplies to current and new customers Unifill placement onto stability studies Potential for additional access or royalty fees Commercial supply agreements Agreements for additional products within portfolio Develop or customize Unilife devices to address specific customer needs fo

  17. Slide 17: Questions

    Questions uniuire?

Unilife — Q1 2012 Earnings Presentation on 6ix